TOR Pathway
Изображение, созданное ИИ
Next-generation cancer drug shows anti-aging effects in yeast
Сообщено ИИ Изображение, созданное ИИ Проверено фактами
Researchers at Queen Mary University of London have found that rapalink-1, an experimental TOR inhibitor being investigated for cancer therapy, extends the lifespan of fission yeast. The study also uncovered a role for agmatinases in regulating the TOR pathway through a metabolic feedback loop, suggesting potential links between diet, gut microbes, and aging.